| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
947 |
886 |
$306K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
12,689 |
11,223 |
$236K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
419 |
376 |
$205K |
| 94010 |
|
1,325 |
1,273 |
$200K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,468 |
2,386 |
$175K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
703 |
677 |
$87K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,101 |
1,065 |
$81K |
| 71046 |
Radiologic examination, chest; 2 views |
1,002 |
963 |
$77K |
| 80053 |
Comprehensive metabolic panel |
8,522 |
7,469 |
$64K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
740 |
645 |
$60K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,888 |
8,107 |
$51K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
849 |
821 |
$48K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
206 |
119 |
$48K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
642 |
620 |
$38K |
| 90791 |
Psychiatric diagnostic evaluation |
250 |
240 |
$35K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
619 |
560 |
$28K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
184 |
118 |
$24K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
207 |
147 |
$21K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
77 |
30 |
$20K |
| 94664 |
|
290 |
283 |
$20K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,910 |
1,820 |
$18K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
166 |
154 |
$15K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,934 |
1,856 |
$12K |
| 80061 |
Lipid panel |
1,311 |
1,271 |
$10K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
78 |
13 |
$9K |
| 82728 |
|
1,387 |
1,297 |
$8K |
| 80050 |
General health panel |
37 |
36 |
$6K |
| 70360 |
|
91 |
85 |
$6K |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
19 |
13 |
$6K |
| 87428 |
|
136 |
134 |
$6K |
| 83540 |
|
1,199 |
1,131 |
$6K |
| 94060 |
|
19 |
19 |
$5K |
| 95012 |
|
225 |
204 |
$5K |
| 84466 |
|
912 |
855 |
$5K |
| 99215 |
Prolong outpt/office vis |
135 |
121 |
$5K |
| 83615 |
|
1,208 |
1,102 |
$3K |
| 97162 |
|
14 |
14 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
56 |
54 |
$3K |
| 84439 |
|
442 |
415 |
$3K |
| 90686 |
|
131 |
122 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
110 |
106 |
$2K |
| 81001 |
|
973 |
901 |
$2K |
| 82948 |
|
473 |
402 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
206 |
154 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
73 |
73 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
73 |
73 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
64 |
56 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,197 |
948 |
$2K |
| 85610 |
|
378 |
273 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
12 |
12 |
$1K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
12 |
12 |
$1K |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,259 |
394 |
$1K |
| 82607 |
|
144 |
137 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
38 |
36 |
$900.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
139 |
123 |
$824.55 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
18 |
18 |
$821.28 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
44 |
44 |
$768.74 |
| 87430 |
|
27 |
26 |
$701.44 |
| 99490 |
Ccm add 20min |
314 |
295 |
$611.07 |
| 84703 |
|
70 |
65 |
$587.92 |
| 80076 |
|
44 |
44 |
$573.42 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
97 |
87 |
$547.81 |
| 81003 |
|
376 |
348 |
$526.50 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
359 |
296 |
$516.58 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
12 |
12 |
$500.30 |
| 0071A |
|
13 |
13 |
$487.80 |
| 82043 |
|
113 |
108 |
$448.09 |
| 85027 |
|
41 |
41 |
$432.12 |
| 86780 |
|
37 |
37 |
$366.96 |
| 82565 |
|
43 |
43 |
$351.99 |
| 82570 |
|
80 |
75 |
$327.87 |
| 90661 |
|
17 |
17 |
$322.80 |
| 87070 |
|
26 |
25 |
$258.90 |
| 80143 |
|
12 |
12 |
$241.42 |
| 82378 |
|
31 |
24 |
$240.88 |
| 86803 |
|
71 |
71 |
$237.16 |
| 80179 |
|
12 |
12 |
$225.76 |
| 84484 |
|
26 |
12 |
$212.42 |
| 88142 |
|
12 |
12 |
$204.24 |
| J2704 |
Injection, propofol, 10 mg |
205 |
172 |
$156.51 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
231 |
144 |
$128.35 |
| 0002A |
|
12 |
12 |
$120.00 |
| 0003A |
|
81 |
81 |
$120.00 |
| 83550 |
|
26 |
24 |
$105.48 |
| 85652 |
|
25 |
24 |
$83.43 |
| 83735 |
|
26 |
24 |
$70.44 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
90 |
49 |
$67.43 |
| 36415 |
Collection of venous blood by venipuncture |
11,478 |
9,191 |
$57.25 |
| 87210 |
|
12 |
12 |
$53.79 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
16 |
13 |
$22.34 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
517 |
307 |
$21.29 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
39 |
36 |
$0.00 |
| 90662 |
|
12 |
12 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
15 |
13 |
$0.00 |
| 36416 |
|
117 |
115 |
$0.00 |
| 91307 |
|
47 |
43 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
96 |
92 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
14 |
14 |
$0.00 |
| A9270 |
Non-covered item or service |
23 |
16 |
$0.00 |
| 83880 |
|
12 |
12 |
$0.00 |